A new laboratory at Brigham and Women’s Hospital is focused on the development of new treatments for chronic lung diseases such as chronic obstructive pulmonary disease (COPD), the third leading cause of death worldwide.
The lab represents a collaborative effort among Partners HealthCare’s founding members Massachusetts General Hospital (MGH) and the Brigham, in coordination with the pharmaceutical company Bayer AG, combining the research and drug development capabilities of the organizations via a team of 20 dedicated to expanding innovation for patients with COPD and related disorders.
“This collaboration is a terrific match of long-standing clinical and research excellence at Brigham Health and Mass General with Bayer’s drug development strength,” said Chris Coburn, Chief Innovation Officer, Partners HealthCare. “This state-of-the-art partnership has emerged from a shared commitment to improving patients’ lives.”
“We strongly believe that this model will significantly accelerate the pace of discovery toward the goal of getting new therapies from the lab to patients safely and efficiently,” said Paul Anderson, MD, PhD, SVP and Chief Academic Officer, Brigham and Women’s Hospital. “This collaboration provides the opportunity to integrate novel findings directly into the drug development pipeline, thus speeding up the time to move a new treatment into the clinic.”
The combined team includes four leading experts who will lend their expertise in the search for new treatment options for patients who suffer from chronic lung diseases: Edwin Silverman, MD, PhD, Chief of the Channing Division of Network Medicine at the Brigham; Bruce Levy, MD, Chief of Pulmonary and Critical Care Medicine at the Brigham; Benjamin Medoff, MD, Chief of Pulmonary and Critical Care at MGH; and Markus Koch, PhD, Head of Preclinical Research, Lung Diseases at Bayer.
Read more on the lab, located at the Brigham, in The Boston Globe.
Banner photo: Senior leaders and scientists from Bayer, Brigham Health, Mass General and Partners HealthCare celebrate the new lab’s launch